free email | research | news | portfolio | charts
 UBBFriend: Email This Page to Someone! |
 Investorville
 A
 AtheroGenics (AGIX)
|
| next newest topic | next oldest topic |
| Author | Topic: AtheroGenics (AGIX) |
|
InvestorGuide Daily Administrator |
posted 08-09-2000 06:14 PM
 
Drug company AtheroGenics (AGIX): priced at $8 , opened at $8, closed at $8.25, and raised $48 million. |
|
Mayor of Investorville Administrator |
posted 02-28-2000 06:35 PM
Biotech company AtheroGenics is developing small-molecule drugs for the treatment of such chronic inflammatory diseases as atherosclerosis (clogging of the arteries), asthma, and rheumatoid arthritis. The company's products prevent the production of inflammatory proteins; its lead product, AGI-1067, is in trials as a treatment for restenosis (the reclosure of arteries after angioplasty). AtheroGenics has identified other compounds that may be used to treat cystic fibrosis and organ transplant rejection. Schering-Plough is helping to develop AGI-1067. The company plans to go public soon and hopes to raise $100 million (source: SEC filing). |
All times are EST (US) | next newest topic | next oldest topic |
  |
|
Powered by: Ultimate Bulletin Board, Version 5.43
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.
Press ctrl-D to bookmark this page for future reference.
By using this site you agree to our Terms of Use.
Copyright 1999 InvestorGuide.com Inc.